<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124303">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811173</url>
  </required_header>
  <id_info>
    <org_study_id>CCMAP</org_study_id>
    <nct_id>NCT01811173</nct_id>
  </id_info>
  <brief_title>Comprehensive-Care for Multimorbid Adults Effectiveness Study</brief_title>
  <acronym>CCMAP</acronym>
  <official_title>The Clalit Comprehensive-Care for Multimorbid Adults Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Israel National Institute for Health Policy and Health Services Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to examine whether directed care of a nurse working jointly with the
      patient's  primary care physician, including a comprehensive assessment, creation of a
      tailored care plan, proactive follow-up, self management support and caregiver support and
      care coordination, can reduce hospital admissions for patients with multiple chronic
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with multi-morbidities pose a significant challenge for healthcare organizations
      because they require continuity of care among a wide range of long-term therapeutic
      paradigms for many different types of diseases. The current study is based on a treatment
      model entailing a nurse-primary care physician team to provide care for patients with
      multiple morbidities.

      Patients in the intervention group who agreed and signed the consent form to participate in
      the study will receive treatment by the physician - nurse team in accordance with the
      components of the Clalit's Comprehensive Care for Mutlimorbid Adults Project model.
      Components of the intervention include:

        1. Comprehensive assessment of the patient's and family's needs

        2. Coordinated care plan based on integrated care guides

        3. &quot;Multimorbid Action Plan&quot; for patients

        4. All-inclussive patient centered care and caregiver support

        5. Proactive monitoring according to the plan.

      Patients in the control groups will receive usual care in their primary care clinics. The
      Usual Care Survey control group will complete study questionnaires at 6, 12 and 24 months
      after enrollement.

      The Usual Care Blinded group will be assessed only retrospectively based on deidentified
      information from Clalit's admistrative databases.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Percent change in admissions for ambulatory care sensetive conditions</measure>
    <time_frame>At enrollment and within 12 months and 24 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ambulatory Care Sensitive Conditions will be defined by ICD-9 codes, based on the classification published by: Ansari, Barbetti, Carson, Auckland, &amp; Cicuttini, 2003 (adapted from Weissman JS, Gatsonis C, Epstein AM ,1992; Millman M, ed. 1993)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergency 30-day readmissions</measure>
    <time_frame>30 days post an index admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>Emergency readmissions are defined as an urgent (via the Emergency Room) admission of one night or longer, following an index admission that lasted 2 nights or longer, in the prior 30 days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in SF-12 Physical and Menal component scores</measure>
    <time_frame>At enrollment and 6, 12, and 24 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Physical and Menal Component scores of the SF-12 measure, as completed by patients through patient interviews</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Chronic Disease</condition>
  <arm_group>
    <arm_group_label>Nurse-physician comprehensive care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comprehensive self management support and care coordination by a nurse-primary care physician team</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care survey control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care blinded control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive usual primary care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nurse-physician comprehensive care</intervention_name>
    <description>Components of the intervention include:
Complete assessment of the patient's and family's needs conducted by the nurse.
Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.
&quot;Multimorbid care plan&quot; integrating all care aspects.
&quot;Action Plan&quot; for patients, supporting self management
Proactive monitoring according to the plan.</description>
    <arm_group_label>Nurse-physician comprehensive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACG system high risk probabilty score  - 4% Highest Risk Score

          -  Age 18 and older

          -  3 or more chronic conditions

        Exclusion Criteria:

          -  Patients already included in a controlled disease management program (e.g., COPD
             disease management and telehealth).

          -  Participation in any medical research.

          -  Confined to bed.

          -  Inpatient nursing care, nursing homes.

          -  Kidney, liver or heart transplant patients.

          -  Active (receipt of oncology chemotherapy , radiotherapy or other oncology treatment
             during the past 3 years).

          -  Dialysis patients.

          -  Clalit Healthcare Services employees.

          -  Patients with major active mental illness, such as schizophrenia.

          -  Cognitive failure.

          -  Non Hebrew speaking patients without Hebrew speaking primary informal caregiver.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ran D Balicer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clalit Research Institute, Clalit Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tali Lang, MA</last_name>
    <phone>(972) 52-8187640</phone>
    <email>tali1981@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Efrat Shadmi, PhD</last_name>
    <phone>(972) 526212182</phone>
    <email>eshadmi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ashdod D</name>
      <address>
        <city>Ashdod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alon Zahava, PhD</last_name>
      <phone>927(08)9306222</phone>
      <email>zahavaa@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ashdod A</name>
      <address>
        <city>Ashdod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yifat Abuhazera, MA</last_name>
      <phone>927(08)8637200</phone>
      <email>yifatabu@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yifat Abuhazera, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azur</name>
      <address>
        <city>Azur</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irena Fuxman, MA</last_name>
      <phone>927(03)5020900</phone>
      <email>IrenaFu@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Irena Fuxman, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramat Yosef</name>
      <address>
        <city>Bat Yam</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taliya Shahnis, BA</last_name>
      <phone>927(03)9376308</phone>
      <email>TalyaSh2@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Taliya Shahnis, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hashikma</name>
      <address>
        <city>Bat Yam</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henri Gigihashvili, PhD</last_name>
      <phone>927(03)5001700</phone>
      <email>Henriye@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arlozorov</name>
      <address>
        <city>Bat YAm</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henri Gigihashvili</last_name>
      <phone>927(03)5001700</phone>
      <email>Henriye@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sokolov</name>
      <address>
        <city>Bat Yam</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henri Gigihashvili, PhD</last_name>
      <phone>927(03)5001700</phone>
      <email>Henriye@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shikun Ammi</name>
      <address>
        <city>Hulon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rama Zilber, MA</last_name>
      <email>taramazi@clalit.org.il</email>
    </contact>
    <contact_backup>
      <phone>927(03)9253808</phone>
    </contact_backup>
    <investigator>
      <last_name>Rama Zilber, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Halutz</name>
      <address>
        <city>Hulon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inna Fidelman, BA</last_name>
      <phone>927(09)7634000</phone>
      <email>ShInaFi@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Inna Fidelman, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lod Center</name>
      <address>
        <city>Lod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zahava Alon</last_name>
      <phone>927(08)9306222</phone>
      <email>Zahavav@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramla Ztafon</name>
      <address>
        <city>Ramla</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Matatov, BA</last_name>
      <phone>927(08)9770056</phone>
      <email>olgam2@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Olga Matatov, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Balfur</name>
      <address>
        <city>Rishon Lezion</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zahava Alon, PhD</last_name>
      <phone>927(08)9036222</phone>
      <email>zahavaa@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Migdal HaIr</name>
      <address>
        <city>Rishon Lezion</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorit Grinberg, MA</last_name>
      <phone>927(03)9595915</phone>
      <email>doritgr@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Dorit Grenberg, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>March 13, 2013</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multimorbidity</keyword>
  <keyword>primary care</keyword>
  <keyword>physician - nurse team</keyword>
  <keyword>proactive monitoring</keyword>
  <keyword>support for self-care</keyword>
  <keyword>primary caregiver</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
